A novel axis, miR-101-3p/mTOR signaling, was first observed to be responsible for radiosensitivity of NSCLC, which will enhance the efficacy of irradiation therapy and improve the survival of NSCLC patients. This evidence concerns the gene MTOR and non-small cell lung carcinoma.